Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914475 | 0.86 | TK1 (0.51) | TK1 | |
| SCHEMBL914474 | 0.86 | TK1 (0.51) | TK1 | |
| SCHEMBL1417674 | 0.85 | TK1 (0.45) | TK1 | |
| SCHEMBL12795961 | 0.85 | TK1 (0.45) | TK1 | |
| SCHEMBL1417676 | 0.85 | TK1 (0.45) | TK1 | |
| SCHEMBL1417610 | 0.85 | TK1 (0.45) | TK1 | |
| SCHEMBL31652938 | 0.85 | TK1 (0.55) | TK1 | |
| SCHEMBL31653051 | 0.85 | TK1 (0.55) | TK1 | |
| SCHEMBL913904 | 0.85 | TK1 (0.55) | TK1 | |
| SCHEMBL913905 | 0.85 | TK1 (0.55) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159351-A2 | MODIFIED 3'-AZIDO-4'-ETHYNYL-NUCLEOSIDES AS ANTIVIRAL AGENTS | Gilead Pharmasset LLC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-1937825-B1 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD PHARMASSET LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8569478-B2 | Modified 4′-nucleosides as antiviral agents | GILEAD PHARMASSET LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110021454-A1 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021454-A1 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, PNP, SAMHD1 | TK1 93/4885TK2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.